These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9635575)

  • 1. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
    Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
    Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
    Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
    Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
    Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
    Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
    Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
    Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
    Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
    Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
    Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
    Khan SR; Denmeade SR
    Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
    DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
    Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
    Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
    Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
    Sinha AA; Quast BJ; Reddy PK; Elson MK; Wilson MJ
    Anticancer Res; 1999; 19(2A):893-902. PubMed ID: 10368631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
    Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
    Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
    Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
    Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
    Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
    Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.